Studying treatments for kidney transplant rejection
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study looks at different treatments for a type of kidney transplant rejection called antibody-mediated rejection, where the body's immune system attacks the new kidney. It aims to understand how these treatments work and how they might help people keep their transplanted kidney healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must already be enrolled in the TAR:GET-1 study, which is a separate study for kidney transplant patients.
- You need to have had a kidney transplant.
- You must have antibody-mediated rejection, a condition where your immune system attacks the new kidney.
- You need to sign a consent form to participate in this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This study looks at how the immune system reacts in kidney transplant patients who may be experiencing rejection. It aims to better understand and improve treatment for transplant rejection.
This study compares two ways of treating acute rejection (when the immune system attacks the new organ) in people who have had a kidney or combined kidney-pancreas transplant. It looks at whether adding a different approach helps protect the transplant long-term.
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This study compares a new medicine called tegoprubart with a standard medicine called tacrolimus for people who are getting a kidney transplant. The goal is to see if the new medicine is safe and works as well as or better than the standard one to keep the new kidney healthy.
Hear when a new Transplant; Complication, Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.